Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18)
Year of publication
Document Type
- Journal article (17)
- Preprint (1)
Language
- English (18)
Keywords
- MYC (4)
- HUWE1 (3)
- MIZ1 (3)
- cancer (2)
- colorectal cancer (2)
- differentiation (2)
- metastasis (2)
- transcription (2)
- transcription factor MIZ-1 (2)
- 28 (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (18)
- Rudolf-Virchow-Zentrum (5)
- Comprehensive Cancer Center Mainfranken (3)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (3)
- Klinik und Poliklinik für Strahlentherapie (2)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Medizinische Klinik und Poliklinik II (1)
- Pathologisches Institut (1)
Formation of the Aurora-A–MYCN complex increases levels of the oncogenic transcription factor MYCN in neuroblastoma cells by abrogating its degradation through the ubiquitin proteasome system. While some small-molecule inhibitors of Aurora-A were shown to destabilize MYCN, clinical trials have not been satisfactory to date. MYCN itself is considered to be `undruggable' due to its large intrinsically disordered regions. Targeting the Aurora-A–MYCN complex rather than Aurora-A or MYCN alone will open new possibilities for drug development and screening campaigns. To overcome the challenges that a ternary system composed of Aurora-A, MYCN and a small molecule entails, a covalently cross-linked construct of the Aurora-A–MYCN complex was designed, expressed and characterized, thus enabling screening and design campaigns to identify selective binders.